+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic



Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic



Journal of Clinical Oncology 19(8): 2247-2253



Purpose: Data from the Breast Cancer Linkage Consortium suggest that the proportion of familial breast and ovarian cancers linked to BRCA1 or BRCA2 may be as high as 98% depending on the characteristics of the families, suggesting that mutations in BRCA1 or BRCA2 may entirely account for hereditary breast and ovarian cancer families. We sought to determine what proportion of families with both breast and ovarian cancers seen in a breast cancer risk evaluation clinic are accounted for by coding region germline mutations in BRCA1 and BRCA2 as compared to a linkage study group. We also evaluated what clinical parameters were predictive of mutation status. Patients and Methods: Affected women from 100 families with at least one case of breast cancer and at least one case of ovarian cancer in the same lineage were screened for germline mutations in the entire coding regions of BRCA1 and BRCA2 by conformation-sensitive gel electrophoresis, apolymerase chain reaction-based heteroduplex analysis, or direct sequencing. Results: Unequivocal deleterious mutations were found in 55% (55 of 100) of the families studied. Mutations in BRCA1 and BRCA2 accounted for 80% and 20% of the mutations overall, respectively. Using multivariate analysis, the strongest predictors of detecting a mutation in BRCA1 or BRCA2 in this study group were the presence of a single family member with both breast and ovarian cancer (P < .0009; odds ratio (OR), 5.68; 95% confidence interval (CI), 2.04 to 15.76) and a young average age at breast cancer diagnosis in the family (P < .0016; OR, 1.69; 95% CI, 1.23 to 2.38). Conclusion: These results suggest that at least half of breast/ovarian families evaluated in a high-risk cancer evaluation clinic may have germline mutations in BRCA1 or BRCA2. Whether the remaining families have mutations in noncoding regions in BRCA1, mutations in other, as-yet-unidentified, low-penetrance susceptibility genes, or represent chance clustering remains to be determined.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010715659

Download citation: RISBibTeXText

PMID: 11304778

DOI: 10.1200/jco.2001.19.8.2247


Related references

Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. Human Mutation 18(6): 545, 2001

Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Human Mutation 23(2): 205, 2004

BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Research and Treatment 128(1): 211-218, 2011

Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes and Cancer 33(3): 235-242, 2002

Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Human Mutation 20(3): 235, 2002

Germline Brca1/Brca2 Mutations in Breast/ovarian Cancer Families in Croatia: Identification of Three Novel Mutations. European Journal of Cancer 48: S274-S275, 2012

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. British Journal of Cancer 79(9-10): 1475-1478, 1999

BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Disease Markers 28(6): 377-384, 2010

BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. Gynecologic Oncology 125(3): 687-692, 2012

Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Human Mutation 15(5): 480-481, 2000

Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN. Clinical Genetics 77(2): 193-196, 2010

BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pacific Journal of Cancer Prevention 4(3): 203-208, 2003

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Breast Cancer Research and Treatment 100(1): 83-91, 2006

Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Human Genetics 112(5-6): 542-551, 2003

Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families. Human Mutation 17(1): 74, 2001